TROY is a promising prognostic biomarker in patients with colorectal cancer

Nishioka,Mitsuaki; Suehiro,Yutaka; Sakai,Kouhei; Matsumoto,Toshihiko; Okayama,Naoko; Mizuno,Hidekazu; Ueno,Koji; Suzuki,Nobuaki; Hashimoto,Shinichi; Takami,Taro; Hazama,Shoichi; Nagano,Hiroaki; Sakaida,Isao; Yamasaki,Takahiro

doi:10.3892/ol.2018.8079

TROY is a promising prognostic biomarker in patients with colorectal cancer

Authors:
- Mitsuaki Nishioka
- Yutaka Suehiro
- Kouhei Sakai
- Toshihiko Matsumoto
- Naoko Okayama
- Hidekazu Mizuno
- Koji Ueno
- Nobuaki Suzuki
- Shinichi Hashimoto
- Taro Takami
- Shoichi Hazama
- Hiroaki Nagano
- Isao Sakaida
- Takahiro Yamasaki
View Affiliations

Affiliations: Division of Laboratory, Yamaguchi University Hospital, Ube, Yamaguchi 755-8505, Japan, Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan, Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan, Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan, Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan, Department of Translational Research and Developmental Therapeutics against Cancer, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
Published online on: February 16, 2018 https://doi.org/10.3892/ol.2018.8079
Pages: 5989-5994

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor receptor superfamily member 19 (TROY) is involved in the Wnt/β-catenin signaling pathway and interacts with leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), which is a well-known biomarker of cancer stem cells and a prognostic marker of colorectal cancer (CRC). Because there have been no studies to evaluate the prognostic significance of TROY, we performed the present study to determine whether TROY can be a prognostic biomarker in CRC patients. We evaluated TROY expression levels in 100 CRC tissues by quantitative real-time PCR and investigated the association of TROY expression levels with clinicopathologic features. Cancer stage and TROY expression level were found to be independent prognostic factors of disease-free survival. Moreover, TROY overexpression was the sole independent prognostic factor of disease-free survival in patients with stage II and III CRC. These results suggest that analysis of TROY might help predict clinical outcome in patients with CRC. To support our findings, confirmatory studies using independent data sets are needed.

View Figures

View References

1	GLOBOCAN 2012. 11–June. 2017http://globocan.iarc.fr/
2	CANCERSTATISTICSINJAPAN'15. 11–June. 2017http://ganjoho.jp/en/professional/statistics/brochure/2015_en.html
3	Böckelman C, Engelmann BE, Kaprio T, Hansen TF and Glimelius B: Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature. Acta Oncol. 54:5–16. 2015. View Article : Google Scholar : PubMed/NCBI
4	Verhoeff SR, van Erning FN, Lemmens VE, de Wilt JH and Pruijt JF: Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer. 139:187–193. 2016. View Article : Google Scholar : PubMed/NCBI
5	Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
6	MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
7	Schneikert J and Behrens J: The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut. 56:417–425. 2007. View Article : Google Scholar : PubMed/NCBI
8	Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ and Clevers H: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 449:1003–1007. 2007. View Article : Google Scholar : PubMed/NCBI
9	Barker N and Clevers H: Leucine-rich repeat-containing G-protein-coupled receptors as markers of adult stem cells. Gastroenterology. 138:1681–1696. 2010. View Article : Google Scholar : PubMed/NCBI
10	Hirsch D, Barker N, McNeil N, Hu Y, Camps J, McKinnon K, Clevers H, Ried T and Gaiser T: LGR5 positivity defines stem-like cells in colorectal cancer. Carcinogenesis. 35:849–858. 2014. View Article : Google Scholar : PubMed/NCBI
11	Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ and Clevers H: Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 457:608–611. 2009. View Article : Google Scholar : PubMed/NCBI
12	Hu S, Tamada K, Ni J, Vincenz C and Chen L: Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily. Genomics. 62:103–107. 1999. View Article : Google Scholar : PubMed/NCBI
13	Fafilek B, Krausova M, Vojtechova M, Pospichalova V, Tumova L, Sloncova E, Huranova M, Stancikova J, Hlavata A, Svec J, et al: Troy, a tumor necrosis factor receptor family member, interacts with lgr5 to inhibit wnt signaling in intestinal stem cells. Gastroenterology. 144:381–391. 2013. View Article : Google Scholar : PubMed/NCBI
14	Spanjaard RA, Whren KM, Graves C and Bhawan J: Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target. Int J Cancer. 120:1304–1310. 2007. View Article : Google Scholar : PubMed/NCBI
15	Paulino VM, Yang Z, Kloss J, Ennis MJ, Armstrong BA, Loftus JC and Tran NL: TROY (TNFRSF19) is overexpressed in advanced glial tumors and promotes glioblastoma cell invasion via Pyk2-Rac1 signaling. Mol Cancer Res. 8:1558–1567. 2010. View Article : Google Scholar : PubMed/NCBI
16	Loftus JC, Dhruv H, Tuncali S, Kloss J, Yang Z, Schumacher CA, Cao B, Williams BO, Eschbacher JM and Ross JT: TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance. Mol Cancer Res. 11:865–874. 2013. View Article : Google Scholar : PubMed/NCBI
17	Schön S, Flierman I, Ofner A, Stahringer A, Holdt LM, Kolligs FT and Herbst A: β-catenin regulates NF-κB activity via TNFRSF19 in colorectal cancer cells. Int J Cancer. 135:1800–1811. 2014. View Article : Google Scholar : PubMed/NCBI
18	Sobin LH, Gospodarowicz MK and Wittekind C: TNM classification of malignant tumours. 7th. Hoboken Wiley-Blackwell; pp. 3362009
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Yamamoto Y, Sakamoto M, Fujii G, Tsuiji H, Kenetaka K, Asaka M and Hirohashi S: Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology. 37:528–533. 2003. View Article : Google Scholar : PubMed/NCBI
21	Tanese K, Fukuma M, Yamada T, Mori T, Yoshikawa T, Watanabe W, Ishiko A, Amagai M, Nishikawa T and Sakamoto M: G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. Am J Pathol. 173:835–843. 2008. View Article : Google Scholar : PubMed/NCBI
22	Sun B, Ye X, Li Y and Zhang W: Lgr5 is a potential prognostic marker in patients with cervical carcinoma. Int J Clin Exp Pathol. 8:1783–1789. 2015.PubMed/NCBI
23	Sun Y, Jia X and Wu X: High expressions of Lgr5 and ALDH1 in primary epithelial ovarian cancer correlate with advanced tumor stage and grade as well as poor prognosis of the patients. Gynecol Obstet Invest. 20–Jun;2015.(Epub ahead of print). View Article : Google Scholar
24	Takahashi H, Ishii H, Nishida N, Takemasa I, Mizushima T, Ikeda M, Yokobori T, Mimori K, Yamamoto H, Sekimoto M, et al: Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Ann Surg Oncol. 18:1166–1174. 2011. View Article : Google Scholar : PubMed/NCBI
25	Wu XS, Xi HQ and Chen L: Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol. 10:2442012. View Article : Google Scholar : PubMed/NCBI
26	Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Kawamura M, Okugawa Y, Okigami M, Hiro J, Uchida K, Mohri Y and Kusunoki M: Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy. J Cancer Res Clin Oncol. 139:131–138. 2013. View Article : Google Scholar : PubMed/NCBI
27	Hsu HC, Liu YS, Tseng KC, Hsu CL, Liang Y, Yang TS, Chen JS, Tang RP, Chen SJ and Chen HC: Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. Int J Colorectal Dis. 28:1535–1546. 2013. View Article : Google Scholar : PubMed/NCBI
28	Barker N, Tan S and Clevers H: Lgr proteins in epithelial stem cell biology. Development. 140:2484–2494. 2013. View Article : Google Scholar : PubMed/NCBI
29	Dhruv HD, Roos A, Tomboc PJ, Tuncali S, Chavez A, Mathews I, Berens ME, Loftus JC and Tran NL: Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway. J Neurooncol. 126:397–404. 2016. View Article : Google Scholar : PubMed/NCBI